National Psoriasis Foundation is solely responsible for all content and development.
TreatmentJanuary 11, 2021
Learn About ILUMYA® (tildrakizumab-asmn) and Why Biologic Treatments May be Right for You
Watch this webinar to hear Dr. Neal Bhatia, Director and Clinical Dermatology Principal Investigator at Therapeutics Clinical Research, discuss moderate-to-severe plaque psoriasis, the benefits of biologic treatments, and provide an overview of ILUMYA® (tildrakizumab-asmn) as a treatment option. We also hear from Jim, one of Dr. Bhatia’s patients currently taking ILUMYA®, who shares his journey with moderate-to-severe plaque psoriasis and how he found a biologic treatment that works for him. Dr. Bhatia answers some frequently asked questions and shares some new research in the field of biologics.
ILUMYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills, or phototherapy. Healthcare providers should check the patient for infections and tuberculosis before starting treatment with ILUMYA®. Before starting any treatment, patients should talk to their doctor and review the important safety information to understand the potential risks. The most common (≥1%) adverse reactions associated with ILUMYA® are upper respiratory infections, injection site reactions, and diarrhea.
This webinar is sponsored by Sun Pharma. For Important Safety Information: https://bit.ly/2We7fIS.
This webinar is sponsored by: